1stOncology™: Cancer Intelligence Service – Page 14221 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Calithera to Participate in the 8th Annual SVB Leerink Global Healthcare Conference

On February 22, 2019 Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, reported that Susan Molineaux, Ph.D, the company’s founder, president and chief executive officer, will participate in a fireside chat at the SVB Leerink Global Healthcare Conference at 3:30 p.m. ET on Thursday, February 28, 2019 in New York City (Press release, Calithera Biosciences, FEB 22, 2019, View Source [SID1234535229]). The presentation will be webcast live and available for replay for up to 30 days at www.calithera.com in the Investor Relations section.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Polaris Group Announces Dr. Shaw Chen as New Interim CEO

On February 22, 2019 Polaris Group reported that Shaw Chen, M.D., Ph.D. has been appointed as the Interim Chief Executive Officer (Press release, Polaris Pharmaceuticals, FEB 22, 2019, View Source [SID1234534439]).

After more than 26 years with the FDA where he was the Deputy Director in the Office of Drug Evaluation, Center for Drug Evaluation and Research, Dr. Chen brings a wealth of expertise and institutional knowledge to Polaris Group. With his experience in FDA regulatory processes, Dr. Chen will be an invaluable asset as Polaris Group works to streamline the clinical development of its lead anti-cancer compound, ADI-PEG 20.

"The insight into the FDA that Dr. Chen has will be extremely valuable as we move forward with clinical investigations of ADI-PEG 20," said John Bomalaski, Executive Vice President of Medical Affairs at Polaris. "We are thrilled to work with him while we continue to search for a permanent CEO."

About ADI‑PEG 20

ADI‑PEG 20 is a biologic being developed by Polaris Group to treat cancers carrying a major metabolic defect that renders them unable to internally synthesize arginine. Because arginine is essential for protein synthesis and survival of cells, these cancer cells become dependent upon the external supply of arginine to survive and grow. ADI‑PEG 20 is designed to deplete the external supply of arginine, causing arginine-dependent cancer cells to die while leaving the patient’s normal cells unharmed. Multiple cancers have been reported to have a high degree of arginine-dependency and can potentially be treated with ADI‑PEG 20.

First-in-Human Trial Using BXQ-350 for the Treatment of Cancer

On February 22, 2019 Bexion Pharmaceuticals, Inc. (Bexion) reported the opening of Part 3 of their Phase I First-In-Human Trial using BXQ-350 for the treatment of cancer (Press release, Bexion, FEB 22, 2019, View Source [SID1234533802]). This trial was designed to determine the maximum tolerated dose of BXQ-350 and to characterize its safety and pharmacokinetics.

The Phase I Part 1 study showed that BXQ-350 was well tolerated at all five doses tested with no dose limiting toxicities observed and with no serious adverse events attributed to the therapy. Part 2 tested the highest dose in an additional 36 solid tumor patients. Preliminary data support a safe and tolerable drug profile. The purpose of Part 3 will be to explore safety, and additional indications in rare and gastrointestinal tumors.

"By enrolling patients in Part 3, we hope to gain a better understanding of the potential of BXQ-350 in treating cancer," stated Dr. Ray Takigiku, Founder and CEO of Bexion.

FibroGen to Report Fourth Quarter and Full Year 2018 Financial Results

On February 22, 2019 FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, reported that it will report fourth quarter and full year 2018 financial results on Wednesday, February 27, 2019 after market close, and will host a conference call to discuss financial results and provide a business update at 5:00 p.m. ET (2:00 p.m. PT) (Press release, FibroGen, FEB 22, 2019, View Source;p=irol-newsArticle&ID=2388639 [SID1234533605]).

Conference Call and Audio Webcast
Interested parties may access a live audio webcast of the conference call via the investor section of the FibroGen website, www.fibrogen.com. It is recommended that listeners access the website 15 minutes prior to the start of the call to download and install any necessary audio software. A replay of the webcast will be available shortly after the call for a period of two weeks. To access the replay, please dial (888) 843-7419 (domestic) or (630) 652-3042 (international), and use passcode 48309188#.

Dial-In Information
Live (U.S./Canada): (888) 771-4371
Live (International): (847) 585-4405
Confirmation number: 48309188

Constellation Pharmaceuticals to Present at Upcoming Investor Conferences

On February 22, 2019 Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, reported that Jigar Raythatha, CEO, will present at the SVB Leerink Global Healthcare Conference in New York at 9:00 AM EST on Friday, March 1, and at the Cowen and Company Health Care Conference in Boston at 11:20 AM EDT on Monday, March 11 (Press release, Constellation Pharmaceuticals, FEB 22, 2019, View Source [SID1234533603]). Live audio webcasts of these presentations and archives for replay will be available on the Investor Relations section of Constellation’s website at View Source The audio webcast replays will be available for 90 days following the live presentation.